Genmab — Marts 2023
-
Collaborations with Genmab and Innovent developing next-generation Boltbody ISACs continue to progress. Both collaborations are exploring proprietary linker-payloads from the Boltbody ISAC platform, combining with Genmab’s proprietary bispecific
antibodies -
BOLT også ude med vag PR på deres HER2 ISAC https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-announces-positive-topline-data-bdc-1001
-
Den optur, der startede 10. marts synes sat lidt på pause. Håber på lidt positivt nyt, der kan give fornyede kræfter.
-
interesting, a new Epcoritamab trial +Venetoclax by the Haemato Oncology Foundation in the Netherlands, with Nordic & German CLL Study Groups, don't see genmab or abbvie - Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (AETHER) https://clinicaltrials.gov/ct2/show/NCT05791409
-
Amivantamab efficacy in pretreated NSCLC with EGFR Exon 20 insertion mutations persists long term https://dailyreporter.esmo.org/european-lung-cancer-congress-2023/elcc-2023/amivantamab-efficacy-in-pretreated-nsclc-with-egfr-exon-20-insertion-mutations-persists-long-term
-
https://twitter.com/tnewsomdavis/status/1641480986746662913 "Very surprised that 1/3 of audience opted
for 1L Amivantamab" -
Daratumumab, an anti-CD38 effective in two cases of severe refractory myositis https://www.institut-myologie.org/en/2023/03/30/daratumumab-an-anti-cd38-effective-in-two-cases-of-severe-refractory-myositis/
-
Morn, Fibonacci købssignal https://www.proinvestor.com/boards/111776/
-
https://onkologisktidsskrift.dk/behandlinger/lungekraeft/2835-nye-data-for-rybrevant-bekraefter-stoffets-potentiale-mod-egfr-exon-20-muteret-nsclc.html Nye data for Rybrevant bekræfter stoffets potentiale mod EGFR exon 20-muteret NSCLC
-
AMGEN on Horizon acquisition: We believe that our decades of leadership in inflammation and nephrology, combined with our global presence and world-class biologic capabilities, will enable us to reach many more patients with life-changing medicines like TAVNEOS and TEPEZZA than either company could achieve on its own. https://www.amgen.com/stories/2023/03/2022-letter-to-shareholders
-
Nå mon vi skal have et positivt udfald af voldgift før 3000 kan brydes og agere ny bund. NPV impact er signifikant større på udfaldet af den afgørelse end af epco. Så bliver rart at komme på den anden side af retssagen. At få reduceret usikkerheden der tynger
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind